boostrix-ipv
glaxosmithkline nz limited - diphtheria toxoid, adsorbed 2 [iu] (2.5lfu); pertactin 2.5ug; ; pertussis filamentous haemagglutinin 8ug; ; pertussis toxoid, adsorbed 8ug; ; polio virus type 1 40 dagu; ; polio virus type 2 8 dagu; ; polio virus type 3 32 dagu; ; tetanus toxoid 20 [iu] (5lfu) - suspension for injection - 0.5 ml - active: diphtheria toxoid, adsorbed 2 [iu] (2.5lfu) pertactin 2.5ug pertussis filamentous haemagglutinin 8ug pertussis toxoid, adsorbed 8ug polio virus type 1 40 dagu polio virus type 2 8 dagu polio virus type 3 32 dagu tetanus toxoid 20 [iu] (5lfu) excipient: aluminium medium 199 sodium chloride water for injection - boostrix®-ipv is indicated for booster vaccination against diphtheria, tetanus, pertussis and poliomyelitis of individuals from the age of four years onwards. boostrix®-ipv is not intended for primary immunisation.
infanrix hexa vaccine
glaxosmithkline pte ltd - diphtheria toxoid; filamentous haemagglutinin; hepatitis b surface antigen (purified); hib purified capsular polysaccharide bound to tetanus toxoid; pertactin (69 kda omp); pertussis toxoid; poliovirus type 1 (inactivated); poliovirus type 2 (inactivated); poliovirus type 3 (inactivated) - injection - min 30 iu/0.5 ml - diphtheria toxoid min 30 iu/0.5 ml; filamentous haemagglutinin 25 mcg/0.5 ml; hepatitis b surface antigen (purified) 10 mcg/0.5 ml; hib purified capsular polysaccharide bound to tetanus toxoid 10 mcg/0.5 ml; pertactin (69 kda omp) 8 mcg/0.5 ml; pertussis toxoid 25 mcg/0.5 ml; poliovirus type 1 (inactivated) 40 du/0.5 ml; poliovirus type 2 (inactivated) 8 du/0.5 ml; poliovirus type 3 (inactivated) 32 du/0.5 ml
boostrix vaccine
glaxosmithkline pte ltd - diphtheria toxoid; filamentous haemagglutinin; pertactin; pertussis toxoid; tetanus toxoid - injection - 2 iu/0.5 ml - diphtheria toxoid 2 iu/0.5 ml; filamentous haemagglutinin 8 mcg/0.5 ml; pertactin 2.5 mcg/0.5 ml; pertussis toxoid 8 mcg/0.5 ml; tetanus toxoid 20 iu/0.5 ml
infanrix-ipv vaccine suspension for injection 0.5ml pre-filled syringes
glaxosmithkline uk ltd - diphtheria toxoid; tetanus toxoid; pertussis antigens; human poliovirus type 1 inactivated; human poliovirus type 2 inactivated; human poliovirus type 3 inactivated - suspension for injection
infanrix-ipv + hib vaccine powder and suspension for suspension for injection 0.5ml pre-filled syringes
glaxosmithkline uk ltd - diphtheria toxoid; tetanus toxoid; pertussis antigens; human poliovirus type 1 inactivated; human poliovirus type 2 inactivated; human poliovirus type 3 inactivated; haemophilus influenzae type b polysaccharide protein conjugate - powder and suspension for suspension for injection
boostrix
glaxosmithkline nz limited - diphtheria toxoid, adsorbed 2 [iu] (lower fiducial limit); pertactin 2.5ug; ; pertussis filamentous haemagglutinin 8ug; ; pertussis toxoid, adsorbed 8ug; ; tetanus toxoid, adsorbed 20 [iu] (lower fiducial limit); diphtheria toxoid, adsorbed 2 [iu] (lower fiducial limit); pertactin 2.5ug; pertussis filamentous haemagglutinin 8ug; pertussis toxoid, adsorbed 8ug; tetanus toxoid, adsorbed 20 [iu] (lower fiducial limit) - suspension for injection - 0.5 ml - active: diphtheria toxoid, adsorbed 2 [iu] (lower fiducial limit) pertactin 2.5ug pertussis filamentous haemagglutinin 8ug pertussis toxoid, adsorbed 8ug tetanus toxoid, adsorbed 20 [iu] (lower fiducial limit) excipient: aluminium hydroxide aluminium phosphate formaldehyde glycine phenoxyethanol polysorbate 80 sodium chloride water for injection active: diphtheria toxoid, adsorbed 2 [iu] (lower fiducial limit) pertactin 2.5ug pertussis filamentous haemagglutinin 8ug pertussis toxoid, adsorbed 8ug tetanus toxoid, adsorbed 20 [iu] (lower fiducial limit) excipient: aluminium hydroxide aluminium phosphate sodium chloride water for injection - boostrix is indicated for booster vaccination against diphtheria, tetanus and pertussis of individuals aged four years and older.
infanrix-hexa
glaxosmithkline nz limited - diphtheria toxoid, adsorbed 30 [iu] (not less than); hepatitis b surface antigen, recombinant 10ug; pertactin 8ug; ; pertussis filamentous haemagglutinin 25ug; ; pertussis toxoid, adsorbed 25ug; ; polio virus type 1 40 dagu (/dose); ; polio virus type 2 8 dagu (/dose); ; polio virus type 3 32 dagu (/dose); ; tetanus toxoid, adsorbed 40 [iu] (not less than); haemophilus influenzae vaccine, tetanus toxoid conjugate 10ug (covalently bonded to tetanus toxoid 20 - 40micrograms); - suspension for injection - 0.5 ml - active: diphtheria toxoid, adsorbed 30 [iu] (not less than) hepatitis b surface antigen, recombinant 10ug pertactin 8ug pertussis filamentous haemagglutinin 25ug pertussis toxoid, adsorbed 25ug polio virus type 1 40 dagu (/dose) polio virus type 2 8 dagu (/dose) polio virus type 3 32 dagu (/dose) tetanus toxoid, adsorbed 40 [iu] (not less than) excipient: aluminium medium 199 sodium chloride water for injection active: haemophilus influenzae vaccine, tetanus toxoid conjugate 10ug (covalently bonded to tetanus toxoid 20 - 40micrograms) excipient: aluminium as aluminium phosphate lactose - infanrix hexa is indicated for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and haemophilus influenzae type b.
boostrix
glaxo smith kline (israel) ltd - diphtheria toxoid; filamentous haemagglutinin (fha); pertactin (prn or 69 kda omp); pertussis toxoid (pt); tetanus toxoid - suspension for injection - diphtheria toxoid nlt 2 iu / 0.5 ml; tetanus toxoid nlt 20 iu / 0.5 ml; filamentous haemagglutinin (fha) 8 mcg / 0.5 ml; pertussis toxoid (pt) 8 mcg / 0.5 ml; pertactin (prn or 69 kda omp) 2.5 mcg / 0.5 ml - tetanus toxoid, combinations with diphtheria toxoid - tetanus toxoid, combinations with diphtheria toxoid - for booster vaccination against diphtheria, tetanus and pertussis of individuals from the age of four years onwards.the administration of boostrix should be based on official recommendations
infanrix hexa
glaxo smith kline (israel) ltd - diphtheria toxoid; filamentous haemagglutinin (fha); haemophilus b; hepatitis b vaccines; pertactin; pertussis toxoid (pt); poliovirus type 1 inactivated; poliovirus type 2 inactivated; poliovirus type 3 inactivated; tetanus toxoid - powder and suspension for suspension for injection - filamentous haemagglutinin (fha) 25 mcg/dose; diphtheria toxoid nlt 30 iu/dose; tetanus toxoid nlt 40 iu/dose; hepatitis b vaccines 10 mcg/dose; poliovirus type 1 inactivated 40 du/dose; poliovirus type 2 inactivated 8 du/dose; poliovirus type 3 inactivated 32 du/dose; haemophilus b 10 mcg/dose; pertactin 8 mcg/dose; pertussis toxoid (pt) 25 mcg/dose - bacterial and viral vaccines, combined - infantix hexa is indicated for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and disease caused by haemophilus influenza type b for infants between 6 weeks and 36 months of age.
infanrix ipv+hib vaccine
glaxosmithkline pte ltd - diphtheria toxoid (d); filamentous haemagglutinin (fha); hib purified capsular polysaccharide; pertactin (prn or 69kda outer membrane protein); pertussis toxoid (pt); polio virus type 1 (inactivated); polio virus type 2 (inactivated); polio virus type 3 (inactivated); tetanus toxoid (t) - injection - min 30iu/0.5ml - diphtheria toxoid (d) min 30iu/0.5ml; filamentous haemagglutinin (fha) 25mcg/0.5ml; hib purified capsular polysaccharide 10 mcg/0.5 ml; pertactin (prn or 69kda outer membrane protein) 8mcg/0.5ml; pertussis toxoid (pt) 25mcg/0.5ml; polio virus type 1 (inactivated) 40du/0.5ml; polio virus type 2 (inactivated) 8du/0.5ml; polio virus type 3 (inactivated) 32du/0.5ml; tetanus toxoid (t) min 40iu/0.5ml